DURYSTA™ Glaucoma Treatment
DURYSTA™ is the first, newly FDA-approved biodegradable sustained-release implant that reduces eye pressure, also called intraocular pressure (IOP), in patients with open-angle glaucoma or high eye pressure (ocular hypertension).
Harvard Eye Associates is excited to offer this new, innovative glaucoma treatment option to our patients. In fact, we are the first to treat 100 patients with DURYSTA™ in the U.S.
What is DURYSTA™?
DURYSTA™ is a tiny, dissolvable implant that your ophthalmologist administers into your eye. Once within your eye, the implant steadily releases medicine called bimatoprost every day for several months to help reduce the high eye pressure.
Bimatoprost is believed to lower IOP by increasing the outflow of aqueous humor through both the trabecular meshwork (conventional) and uveoscleral routes (unconventional). Elevated IOP presents a major risk factor for glaucomatous field loss. The higher the level of IOP, the greater the likelihood of optic nerve damage and visual field loss.
DURYSTA™ is designed to be used once and may last several months. Some patients continue to benefit from DURYSTA™ even after it has been broken down.
Am I a Good Candidate for DURYSTA™?
This glaucoma treatment may be a good option for you if:
- you want to minimize eye drops without surgery
- are tired of redness and dryness from eye drops
- struggle to remember to take eye drops every day
- you cannot afford the multiple eye drops
- you tried other treatment options and they didn’t work
If you, your family, or friends have glaucoma and find that eye drops are challenging to take or you are not able to use them as prescribed, call our office at (949) 951-2020 to schedule an appointment with our glaucoma specialists to see which treatment option is best for you.
